Abstract
Parkinson’s disease (PD) is a neurodegenerative disorder which is often reduced to a mere dysfunction of motor performance. Non-motor symptoms, however, are frequent impairments in PD and result in a major impact on the patients and their caregivers. The major neuropsychiatric comorbidities depression, anxiety, and psychotic symptoms are briefly discussed. Additionally, a brief outlook on deep brain stimulation and its effect on psychiatric symptoms is provided. Several studies did show that neuropsychiatric symptoms are underdiagnosed and consecutively treated inadequately. All in all more attention should be directed to the detection and treatment of psychiatric symptoms in PD patients in routine clinical settings.
Similar content being viewed by others
References
Aarsland D, Larsen JP, Cummins JL, Laake K (1999) Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 56:595–601
Althaus A, Arranz Becker O, Spottke A, Dengler R, Schneider F, Kloss M, Eggert K, Oertel WH, Dillmann U, Herting B, Classen J, Dodel R (2008) Frequency and treatment of depressive symptoms in a Parkinson’s disease registry. Parkinsonism Relat Disord
Brown R, Jahanshahi M (1995) Depression in Parkinson’s disease: a psychosocial viewpoint. Adv Neurol 65:61–84
Burn DJ (2002) Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson’s disease. Mov Disord 17:445–454
Castelli L, Perozzo P, Zibetti M, Crivelli B, Morabito U, Lanotte M, Cossa F, Bergamasco B, Lopiano L (2006) Chronic deep brain stimulation of the subthalamic nucleus for Parkinson’s disease: effects on cognition, mood, anxiety and personality traits. Eur Neurol 55:136–144
Chen JJ (2004) Anxiety, depression, and psychosis in Parkinson’s disease: unmet needs and treatment challenges. Neurol Clin 22:S63–S90
Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K, Daniels C, Deutschlander A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider GH, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J (2006) A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 355:896–908
Ehmann TS, Beninger RJ, Gawel MJ, Riopelle RJ (1990) Depressive symptoms in Parkinson’s disease: a comparison with disabled control subjects. J Geriatr Psychiatry Neurol 3:3–9
Fenelon G, Goetz CG, Karenberg A (2006) Hallucinations in Parkinson disease in the prelevodopa era. Neurology 66:93–98
Fenelon G, Mahieux F, Huon R, Ziegler M (2000) Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 123(Pt 4):733–745
Fernandez HH, Aarsland D, Fenelon G, Friedman JH, Marsh L, Troster AI, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG (2008) Scales to assess psychosis in Parkinson’s disease: critique and recommendations. Mov Disord 23:484–500
Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH (2003) Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 18:510–514
Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S (2007) Treating dopamimetic psychosis in Parkinson’s disease: structured review and meta-analysis. Eur Neuropsychopharmacol 17:165–171
Ghazi-Noori S, Chung TH, Deane KHO, Rickards H, Clarke CE (2007) Therapies for depression in Parkinson’s disease (Review) Cochrane Database of Systematic Reviews 2003
Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquera G, Cabrera-Valdivia F, Alarcon J, Garcia-Albea E (1994) Parkinsonism exacerbated by paroxetine. Neurology 44:2406
Kerenyi L, Ricaurte GA, Schretlen DJ, McCann U, Varga J, Mathews WB, Ravert HT, Dannals RF, Hilton J, Wong DF, Szabo Z (2003) Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol 60:1223–1229
Kim SE, Choi JY, Choe YS, Choi Y, Lee WY (2003) Serotonin transporters in the midbrain of Parkinson’s disease patients: a study with 123I-beta-CIT SPECT. J Nucl Med 44:870–876
Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF, Benabid AL, Pollak P (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 349:1925–1934
Leentjens A, Van den Akker M, Metsemakers J, Lousberg R, Verhey F (2003) Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord 18:414–418
Marsh L, McDonald WM, Cummings J, Ravina B (2006) Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord 21:148–158
Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM (2004) Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 63:293–300
Nuti A, Ceravolo R, Piccinni A, Dell’Agnello G, Bellini G, Gambaccini G, Rossi C, Logi C, Dell’Osso L, Bonuccelli U (2004) Psychiatric comorbidity in a population of Parkinson’s disease patients. Eur J Neurol 11:315–320
Oertel WH, Hoglinger GU, Caraceni T, Girotti F, Eichhorn T, Spottke AE, Krieg JC, Poewe W (2001) Depression in Parkinson’s disease. An update. Adv Neurol 86:373–383
Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23:183–189 quiz 313
Riedel O, Klotsche J, Spottke A, Deuschl G, Förstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Dodel R, Wittchen HU (2008) Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol 255(2):255–264
Rojo A, Aguilar M, Garolera MT, Cubo E, Navas I, Quintana S (2003) Depression in Parkinson’s disease: clinical correlates and outcome. Parkinsonism Relat Disord 10:23–28
Schneider F, Habel U, Volkmann J, Regel S, Kornischka J, Sturm V, Freund HJ (2003) Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson disease. Arch Gen Psychiatry 60:296–302
Schuurman A, van den Akker M, Ensinck K, Metsemakers J, Knottnerus J, Leentjens A, Buntinx F (2002) Increased risk of Parkinson’s disease after depression: a retrospective cohort study. Neurology 58:1501–1504
Shabnam GN, Th C, Kho D, H R, Ce C (2003) Therapies for depression in Parkinson’s disease. Cochrane Database Syst Rev: CD003465
Starkstein SE, Merello M, Jorge R, Brockman S, Bruce D, Petracca G, Robinson RG (2008) A validation study of depressive syndromes in Parkinson’s disease. Mov Disord 23:538–546
Stein MB, Heuser IJ, Juncos JL, Uhde TW (1990) Anxiety disorders in patients with Parkinson’s disease. Am J Psychiatry 147:217–220
Takeshita S, Kurisu K, Trop L, Arita K, Akimitsu T, Verhoeff NP (2005) Effect of subthalamic stimulation on mood state in Parkinson’s disease: evaluation of previous facts and problems. Neurosurg Rev 28:179–186 discussion 187
Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D (1993) “Panic attacks” in Parkinson’s disease. A long-term complication of levodopa therapy. Acta Neurol Scand 87:14–18
Veazey C, Aki SO, Cook KF, Lai EC, Kunik ME (2005) Prevalence and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 17:310–323
von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, Dodel R (2005) Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 4:473–490
Walsh K, Bennett G (2001) Parkinson’s disease and anxiety. Postgrad Med J 77:89–93
Weintraub D, Hurtig HI (2007) Presentation and management of psychosis in Parkinson’s disease and dementia with Lewy bodies. Am J Psychiatry 164:1491–1498
Weintraub D, Morales KH, Moberg PJ, Bilker WB, Balderston C, Duda JE, Katz IR, Stern MB (2005) Antidepressant studies in Parkinson’s disease: a review and meta-analysis. Mov Disord 20:1161–1169
Weisskopf MG, Chen H, Schwarzschild MA, Kawachi I, Ascherio A (2003) Prospective study of phobic anxiety and risk of Parkinson’s disease. Mov Disord 18:646–651
Wint DP, Okun MS, Fernandez HH (2004) Psychosis in Parkinson’s disease. J Geriatr Psychiatry Neurol 17:127–136
Wolters EC (1999) Dopaminomimetic psychosis in Parkinson’s disease patients: diagnosis and treatment. Neurology 52:S10–S13
Conflict of interest statement
F. Schneider received grants/ research support from AstraZeneca and from Lundbeck in the recent years and is consultant for AstraZeneca, Otsuka and Janssen-Cilag. A. Althaus, V. Backes and R. Dodel have no financial conflicts of interests to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schneider, F., Althaus, A., Backes, V. et al. Psychiatric symptoms in Parkinson’s disease. Eur Arch Psychiatry Clin Neurosci 258 (Suppl 5), 55–59 (2008). https://doi.org/10.1007/s00406-008-5012-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00406-008-5012-4